Aggressive combo therapy takes on tough brain cancer

NCT ID NCT07670026

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether an intensified treatment plan can delay tumor growth in adults with high-risk glioblastoma that was only partially removed or came back quickly. Participants receive higher radiation doses to the remaining tumor, plus chemotherapy and two immunotherapy drugs (sintilimab and bevacizumab) for up to a year. The study will track how long people live without their cancer worsening, overall survival, side effects, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sintilimab, bevacizumab, temozolomide, and higher-dose radiation
What this could lead to: If it works, this could point toward a more effective treatment strategy for high-risk glioblastoma that is hard to treat with standard therapy.
What could go wrong: This is a small, early-phase (phase II) study with only 31 participants, so results may not apply to all patients. The intensified regimen also carries higher risks of side effects like radiation necrosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

The Second Affiliated Hospital,School of Medicine,Zhejiang University
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.